Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13735602 | 0.88 | FAAH (0.30) | FAAHCES1 | |
| SCHEMBL3353972 | 0.79 | — | — | |
| SCHEMBL6416075 | 0.79 | FAAH (0.32) | FAAHCES1 | |
| SCHEMBL18302641 | 0.68 | — | — | |
| SCHEMBL15488269 | 0.68 | — | — | |
| SCHEMBL8499928 | 0.68 | — | — | |
| SCHEMBL109668 | 0.67 | CYP2D6 (0.34) | CYP2D6CYP3A4CYP1A2CYP19A1CYP2C9 | |
| SCHEMBL4595010 | 0.65 | — | — | |
| SCHEMBL11064389 | 0.64 | TLR8 (0.37) | CYP2D6CYP3A4 | |
| SCHEMBL859772 | 0.64 | FAAH (0.40) | FAAHCES1CYP2D6CYP1A2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1506 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4056574-A1 | ACC INHIBITOR AND USE THEREOF | Nanjing Ruijie Pharma Co., Ltd. (CN) | 2022-09-14 | — | — | EP | claimed |
| CN-114599654-A | ACC inhibitor and application thereof | 南京瑞捷医药科技有限公司 | 2022-06-07 | — | — | CN | claimed |
| EP-4748837-A1 | AROMATIC AMIDE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| EP-4743462-A1 | COMPOUNDS COMPRISING A NAPHTHYRIDINE OR PYRIDOPYRIMIDINE CORE AS PTC READ-THROUGH AGENTS | Tay Therapeutics Limited (GB) | 2026-05-20 | — | — | EP | disclosed |
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-3829559-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-3911640-B1 | PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE | ASTRAZENECA AB (SE) | 2026-05-13 | — | — | EP | disclosed |
| CN-122010947-A | Antagonists of adenosine A2a receptors | 阿道尔克斯治疗有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12617796-B2 | Antagonists of the adenosine A2a receptor | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| WO-2026087899-A1 | MODULATORS OF THE GPR17 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731207-A2 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | Merck Sharp & Dohme LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-5627199-A | TREATING SEROTONIN DISORDERS | ELI LILLY AND COMPANY (US) | 1997-05-06 | — | — | US | disclosed |
| US-5624944-A | SEROTONIN RELATED ILLNESS SUCH AS ANXIETY, DEPRESSION, ANTISECRETORY AGENTS FOR GASTRIC JUICE AND DEMENTIA | ELI LILLY AND COMPANY (US) | 1997-04-29 | — | — | US | disclosed |
| US-5594019-A | SEROTONIN DISORDERS | ELI LILLY AND COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5364856-A | Modification of serotonin function | ELI LILLY AND COMPANY (US) | 1994-11-15 | — | — | US | disclosed |
| US-5347013-A | FOR TREATING MAMMALS WITH SEROTONIN RELATED DISORDERS | ELI LILLY AND COMPANY (US) | 1994-09-13 | — | — | US | disclosed |
| EP-0590971-A1 | 6-Heterocyclyl-4-amino-1,3,4,5-tetrahydrobenz CD indoles for treating motion sickness and vomiting | ELI LILLY AND COMPANY (US) | 1994-04-06 | — | — | EP | disclosed |
| EP-0590970-A1 | 6-Heterocyclyl-4-amino-1,2,2a,3,4,5-hexahydrobenz CD indoles for treating motion sickness and vomiting | ELI LILLY AND COMPANY (US) | 1994-04-06 | — | — | EP | disclosed |
| EP-0506363-A1 | 6-Heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[cd]indoles | ELI LILLY AND COMPANY (US) | 1992-09-30 | — | — | EP | disclosed |
| EP-0506369-A1 | 6-Heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz[CD]indoles | ELI LILLY AND COMPANY (US) | 1992-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617796-B2 | Antagonists of the adenosine A2a receptor | ADORA2A, ADORA2B, ADORA3 | FAAH 1457/4885CES1 2644/4885CYP2D6 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.